Cette traduction est en cours de préparation. En attendant, nous affichons temporairement la version originale en anglais.
Entreprise · 21/09/19941 min de lecture
New Drug Applications; Refusal to File; Change in Schedule of Meetings of the Review Committee
Traduction automatique locale · Langue originale de la source
Résumé
The Food and Drug Administration (FDA) is announcing a change in the procedure that the Center for Drug Evaluation and Research (CDER) uses to review its use of its refusal to file (RTF) procedure, by which it refuses to file new drug applications (NDA's) that are facially deficient under FDA's regulations. Since January 1994, the committee has been meeting bi-monthly rather than quarterly. Because the committee will review all RTF decisions rather than only a few, new drug application (NDA) applicants will not need to submit requests for review.
Langue originale de la source: Federal Register — Health and Human ServicesOuvrir le communiqué original →